Sun Liying: evidence chain thinking of drug research and development from the perspective of reviewers

From June 29, 2018 to June 30, 2018, under the guidance of China Pharmaceutical University, Chongqing Municipal Economic and Information Commission, sponsored by pharma.com and China Pharmacy magazine, and organized by Chongqing Kangzhou pharmaceutical big data development and Application Research Institute, Pharma elite club and pharma college, the third China Pharmaceutical R & D · innovation summit and 2018 top 100 list of China's pharmaceutical R & D strength will be released in Chongqing Grand opening of Marriott Hotel, Professor Sun Liying will attend and deliver keynote speech: Guest Speaker: Professor Sun Liying, former FDA review leader, founder of Santai and Beijing Santai cloud Technology Co., Ltd Professor Sun Liying is a doctor of medicine, former FDA review leader / Senior epidemiologist, program director / statistician of NIH National Cancer Institute, director of data bank and organization Bank of surgical prostate center of Duke University, database director of prostate research center of Military Medical University, and military medicine of the United States Director, surgical molecular trauma laboratory, University (USUHS) Before going abroad in 1992, he was a cardiovascular surgeon, deputy director / Associate Professor Speech title: the reviewer's view of evidence chain thinking in drug R & D: 1 Key nodes and main problems of evidence chain in drug registration documents 2 Chinese and Western thinking in evidence chain in drug R & D and its influence 3 Innovative thinking is the basic factor for drug R & D success For more details, please click [weight] "The third China Pharmaceutical R & D Innovation Summit and 2018 top 100 list of China's pharmaceutical R & D strength" will be held soon!